Home Metabolism P450 (e.g. CYP17) chemical Voriconazole

research use only

Voriconazole P450 (e.g. CYP17) chemical

Cat.No.S1442

Voriconazole is a new triazole derivative similar to fluconazole and itraconazole that acts by inhibiting fungal cytochrome P-450-dependent, 14-alpha-sterol demethylase-mediated synthesis of ergosterol.
Voriconazole P450 (e.g. CYP17) chemical Chemical Structure

Chemical Structure

Molecular Weight: 349.31

Jump to

Quality Control

Batch: Purity: 99.99%
99.99

Solubility

In vitro
Batch:

DMSO : 70 mg/mL (200.39 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 22 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 349.31 Formula

C16H14F3N5O

 Storage (From the date of receipt)
CAS No. 137234-62-9 Download SDF Storage of Stock Solutions

Synonyms UK-109496 SMILES CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
P450
In vitro

Voriconazole is active against certain opportunistic filamentous and dimorphic fungi (molds) and yeasts. This compound's in vitro activities are higher than or similar to those of itraconazole and amphotericin B for most of the molds tested, with the exceptions of R. arrhizus and S. schenckii. It inhibits 95% of isolates at ≤1 μg/ml against 448 recent clinical mold isolates.

In vivo

Voriconazole is significantly more effective than itraconazole in reducing Aspergillus content in the lungs of immunocompromised guinea pig with pulmonary aspergillosis. This compound also has been shown to be effective in guinea pigs with experimental pulmonary or intracranial infections caused by C. neoformans. This compound (5 mg/kg/day, i.p.) combined with Amphotericin B (1.25 mg/kg/day, i.p.) significantly reduces the colony counts in the tissues of selected Guinea pigs compared with those in the tissues of the controls. It (5 mg/kg/day, i.p.) combined with Amphotericin B (1.25 mg/kg/day, i.p.) also results in reductions in colony counts in tissues compared with those in the tissues of Guinea pigs treated with caspofungin acetate (the difference is not statistically significant) and improves the survival times but does not sterilize tissues. This chemical (5 mg/kg/day, i.p.) combined with caspofungin acetate (CAS) at either dose reduces colony counts in tissues 1,000-fold over those for the controls and are the only regimens that significantly reduces the numbers of positive cultures.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-09-03)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06582186 NOT_YET_RECRUITING
Aspergillosis Invasive; Fungal Infection; Hematologic Malignancy
University Hospital, Grenoble
 2024-10 PHASE4
NCT07215273 RECRUITING
Invasive Mould Infection
Elion Therapeutics, Inc.
 2026-02-13 PHASE2
NCT07156201 RECRUITING
KCNT1-Related Epilepsy
Actio Biosciences, Inc.
 2025-08-28 PHASE1
NCT06510699 RECRUITING
Fungal Infection; Haematological Malignancy; Blood Cancer; Infectious Disease
The University of Queensland
 2025-04-14 PHASE2
NCT07457203 NOT_YET_RECRUITING
Drug Drug Interaction (DDI)
Beijing Union Pharmaceutical Factory Ltd
 2026-04 PHASE1
NCT07426042 NOT_YET_RECRUITING
Drug-Drug Interactions
Min Kyu Park
 2026-04 PHASE1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am trying to use it in vivo via ip injection. Is the formulation recommended on your website (2% DMSO+30% PEG 300+2% Tween 80+ddH2O) suitable for injection?

Answer:
It can be dissolved in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 8mg/ml clearly. When making the solution, please dissolve this compound in DMSO clearly first. Then add PEG and Tween, after they mixed well, then dilute with water.

Signaling Pathway Map